London, UK

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease2 trials
• Heart failure1 trial
• Macular degeneration1 trial

Phase

• Phase 1/21 trial
• Phase 2/31 trial
• Phase 31 trial

Status

• Active, not recruiting1 trial
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• EyeBiotech Ltd.2 trials
• Colorado Prevention Center1 trial

Running trials

• Recruiting

  A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

  NCT06033950· Phase 3· Colorado Prevention Center· Source

  Contact: Bonaca, MD

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06571045· Phase 2/3· EyeBiotech Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting

Closed trials

• Completed

  A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

  NCT05919693· Phase 1/2· EyeBiotech Ltd.· Source